TH91828B - Main drug for preventing and / or relieving fatigue - Google Patents
Main drug for preventing and / or relieving fatigueInfo
- Publication number
- TH91828B TH91828B TH701003173A TH0701003173A TH91828B TH 91828 B TH91828 B TH 91828B TH 701003173 A TH701003173 A TH 701003173A TH 0701003173 A TH0701003173 A TH 0701003173A TH 91828 B TH91828 B TH 91828B
- Authority
- TH
- Thailand
- Prior art keywords
- main drug
- fatigue
- preventing
- relieving fatigue
- drug
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract 7
- 229940079593 drugs Drugs 0.000 title claims abstract 7
- 235000004611 garlic Nutrition 0.000 claims abstract 3
- 150000003839 salts Chemical class 0.000 claims abstract 3
- 239000011780 sodium chloride Substances 0.000 claims abstract 3
- 239000000126 substance Substances 0.000 claims abstract 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 claims abstract 2
- 240000002234 Allium sativum Species 0.000 claims 2
- OIRDTQYFTABQOQ-GAWUUDPSSA-N 9-β-D-XYLOFURANOSYL-ADENINE Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@H](O)[C@H]1O OIRDTQYFTABQOQ-GAWUUDPSSA-N 0.000 claims 1
- OIRDTQYFTABQOQ-SXVXDFOESA-N Adenosine Natural products Nc1ncnc2c1ncn2[C@@H]3O[C@@H](CO)[C@H](O)[C@@H]3O OIRDTQYFTABQOQ-SXVXDFOESA-N 0.000 claims 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 1
- 229940029983 VITAMINS Drugs 0.000 claims 1
- 229940021016 Vitamin IV solution additives Drugs 0.000 claims 1
- 229960005305 adenosine Drugs 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000001226 triphosphate Substances 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229930003231 vitamins Natural products 0.000 claims 1
- 230000002929 anti-fatigue Effects 0.000 abstract 2
- 244000245420 ail Species 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000003340 mental Effects 0.000 abstract 1
Abstract
การประดิษฐ์นี้จะจัดให้มีตัวยาหลักซึ่งมีผลในการป้องกันและ/หรือบรรเทาความล้าทางร่างกาย และ/หรือความล้าทางใจที่ดีเยี่ยม การประดิษฐ์นี้ยังจัดให้มีตัวยาหลักสำหรับป้องกันและ/หรือบรรเทาความล้าซึ่งประกอบด้วยอะดี โนซีน 5'-ไตรฟอสเฟตหรือเกลือที่ยอมรับได้ในทางสรีรวิทยาของสารดังกล่าวและผลิตภัณฑ์กระเทียม แปรรูปในลักษณะที่ผสมกัน The invention provides a main drug that has effects on preventing and / or relieving physical fatigue. And / or excellent mental fatigue The invention also provides a primary anti-fatigue and / or anti-fatigue drug containing adenosine 5'-triphosphate, or a physiologically acceptable salt of such substances and garlic products. Processed in a mixed manner
Claims (3)
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TH91828B true TH91828B (en) | 2008-10-10 |
| TH91828A TH91828A (en) | 2008-10-10 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR3027228B1 (en) | COMPOSITION COMPRISING A MIXTURE OF PLANT EXTRACTS AND USE FOR ACTING ON GLUCIDIC AND / OR LIPID METABOLISM | |
| MX2010006195A (en) | Liquid enteral nutritional composition with a low specific protein volume. | |
| DK1858340T3 (en) | Foods containing a probiotic and an isolated beta-glucan, and methods for their use | |
| UA88165C2 (en) | Use of trisubstituted benzopyranones | |
| MX2018004715A (en) | Composition comprising a mixture of molecules extracted from chrysanthellum indicum, cynara scolymus and lycium barbarum and use to act on carbohydrate and/or fat metabolism. | |
| CL2007001945A1 (en) | COMPOUNDS DERIVED FROM ALQUILPIRIDAZINA, INHIBITORS OF 11 BETA-HSD1; PROCESS FOR OBTAINING COMPOUNDS; PHARMACEUTICAL COMPOSITION THAT UNDERSTAND THEM; AND USES IN THE TREATMENT OF DIABETES, OBESITY, FOOD INGESTION DISORDER, DISLIPIDE | |
| EP3318251A3 (en) | Composition for preventing or treating obesity or lipid-related metabolic disease | |
| WO2009134086A3 (en) | Pharmaceutical formulation for treatment of cardiovascular disease | |
| MX2007011264A (en) | Nutritional compositions for modulating vitamin c bio-availability. | |
| WO2018013951A9 (en) | Targeting adenosine a2a receptors for the treatment of levodopa-induced dyskinesias | |
| NO20076663L (en) | immunoglobulins | |
| MY153109A (en) | A solid pharmaceutical formulation | |
| TH91828B (en) | Main drug for preventing and / or relieving fatigue | |
| MX2022013541A (en) | Gamma-polyglutamic acid and zinc compositions. | |
| WO2019073127A3 (en) | Composition containing cannabis oil | |
| TH91828A (en) | Main drug for preventing and / or relieving fatigue | |
| PH12020500606A1 (en) | Use of functionalized calcium carbonate as active ingredient | |
| Logovinsky et al. | New composite score demonstrates sensitivity to disease progression and treatment effects | |
| NO20085267L (en) | Derivatives of 2-alkoxy -3,4,5-trihydroxyalkyl amides, preparation and use thereof, as well as compositions containing the same | |
| Gengo | Easy bruising, epistaxis and gastrointestinal bleeding: 2 case reports | |
| TH1680A3 (en) | Food supplement | |
| TH1680C3 (en) | Food supplement | |
| TH1701000998A (en) | ||
| TH170857A (en) | Anti fatigue agent | |
| TH178555A (en) | Heteroerril derivatives Or its pharmaceutical acceptable salt, method of preparation, and pharmaceutical constituents for the prevention or treatment of disease. Associated with PI3 kinase, which has the same thing as active ingredient. |